Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19). Since its emergence, the COVID-19 pandemic has not only distressed medical services but also caused economic upheavals, marking urgent the need for effective therapeutics. The experie...
Saved in:
Main Authors: | Wei-Chung Chiou (Author), Meng-Shiuan Hsu (Author), Yun-Ti Chen (Author), Jinn-Moon Yang (Author), Yeou-Guang Tsay (Author), Hsiu-Chen Huang (Author), Cheng Huang (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ugonin J Acts as a SARS-CoV-2 3C-like Protease Inhibitor and Exhibits Anti-inflammatory Properties
by: Wei-Chung Chiou, et al.
Published: (2021) -
Crystal structure of SARS-CoV-2 papain-like protease
by: Xiaopan Gao, et al.
Published: (2021) -
Molecular docking and dynamic simulations study for repurposing of multitarget coumarins against SARS-CoV-2 main protease, papain-like protease and RNA-dependent RNA polymerase
by: Mai E. Shoman, et al.
Published: (2022) -
Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease
by: Luca Pinzi, et al.
Published: (2021) -
In Silico Drug Repurposing of Penicillins to Target Main Protease Mpro of SARS-CoV-2
by: Baby Krishnaprasad, et al.
Published: (2020)